Calprotectin as a biomarker in rheumatoid arthritis: the potential predictive value of response to treatment

References

• 1. Manfredi M, Hoovels LV, Benucci M et al. Circulating calprotectin (cCLP) in autoimmune diseases. Autoimmun. Rev. 22(5), doi:10.1016/j.autrev.2023.103295 (2023) (Epub ahead of print).
  Google Scholar
• 2. Jarlborg M, Courvoisier DS, Lamacchia C et al. Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res. Ther. 22(1), 105 (2020).
  Medline CASGoogle Scholar
• 3. Ometto F, Friso L, Astorri D et al. Calprotectin in rheumatic diseases. Exp. Biol. Med. 242(8), 859–873 (2017).
  CASGoogle Scholar
• 4. Wang Q, Chen W, Lin J. The role of calprotectin in rheumatoid arthritis. J. Transl. Intern. Med. 7(4), 2126–2131 (2019).
  Google Scholar
• 5. Hurnakova J, Hulejova H, Zavada J et al. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: a large cohort study. PLOS One 12(8), e0183420 (2017).
  MedlineGoogle Scholar
• 6. Jonsson MK, Sundslisaeter NP, Nordal HH et al. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 76(12), 2031–2037 (2017).
  Medline CASGoogle Scholar
• 7. Hurnakova J, Hulejova H, Zavada J et al. Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. Clin. Rheumatol. 37(8), 2055–2062 (2018).
  MedlineGoogle Scholar
• 8. Inciarte-Mundo J, Hernandez MV, Ruiz-Esquide V et al. Serum calprotectin versus acute-phase reactants in the discrimination of inflammatory disease activity in rheumatoid arthritis patients receiving tumor necrosis factor inhibitors: calprotectin, CRP, and ESR in RA patients receiving TNFi. Arthritis Care Res. 68(7), 899–906 (2016).
  CASGoogle Scholar
• 9. Bonelli M, Ferner E, Goschl L et al. Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis. Arthritis Rheum. 65(3), 599–607 (2013).
  Medline CASGoogle Scholar
• 10. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 41(10), 1845–1850 (1998).
  Medline CASGoogle Scholar
• 11. Reed E, Hedstrom AK, Hansson M et al. Presence of autoantibodies in “seronegative” rheumatoid arthritis associates with classical risk factors and high disease activity. Arthritis Res. Ther. 22(1), 170 (2020).
  Medline CASGoogle Scholar
• 12. Centola M, Cavet G, Shen Y et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLOS One 8(4), e60635 (2013).
  Medline CASGoogle Scholar